During pregnancy uterine perfusion increases dramatically from 50 ml min À1 in week 10 of human pregnancy to as much as 1300 ml min À1 at term 1 as a result of increased maternal cardiac output and trophoblastdriven modification of the uterine spiral arteries. Failure of this normal physiological process leads to preeclampsia (PET) and fetal growth restriction (FGR), two of the most challenging obstetric complications. PET leads to multiorgan dysfunction that causes substantial perinatal and maternal morbidity and mortality worldwide; early prevention has proved elusive. 2 FGR affects up to 8% of all pregnancies, and is associated with stillbirth, longterm neurological impairment and adult onset cardiovascular disease; 3 there is no effective treatment. There is an almost linear positive correlation between uterine blood flow (UBF) and fetal size in sheep. 1 Gelfoam embolization of the proximal uterine arteries (UtAs) in sheep results in FGR and high resistance, notched UtA Doppler waveforms when blood flow is reduced by 50%. 4 Similar abnormal Doppler waveforms are observed in human pregnancies that go on to develop both PET or severe FGR, supporting the hypothesis that abnormal UBF underlies both these conditions clinically. 5 Trophoblast invasion is the key to creating passively dilated channels conducting blood to the intervillous space of the placenta. In FGR and PET, there is decreased depth and density of trophoblast invasion 6, 7 and myometrial small arteries show increased vasoconstriction and decreased endothelium-dependent vasodilatation. 8, 9 Vascular endothelial growth factor is essential for angiogenesis during development. 10 Vascular endothelial growth factor (VEGF) gene or protein therapy may prove therapeutically useful in local perivascular applications by stimulating vascular-protective endothelial functions. 11 and as a potential treatment for ischemic heart disease. [12] [13] [14] VEGF-A causes vasodilatation and an increase in blood flow in diverse animal blood vessels and vascular beds, 15, 16 effects mediated partly through its ability to stimulate endothelial production of nitric oxide (NO) and prostacyclin. [17] [18] [19] [20] The fall in utero-placental resistance in normal pregnancy is mediated by interstitial extravillous trophoblast secretion of angiogenic and vasodilator signals such as VEGF, to promote local blood flow to the uterus. In PET, placental-derived sFlt (sFlt1), an antagonist of VEGF is upregulated, resulting in lowered circulating concentrations of free VEGF and causing endothelial dysfunction. 2 We hypothesized that overexpression of VEGF within UtAs would lead to a sustained increase in UBF by enhancing the vasodilatory response to known vasodilators, such as bradykinin (BK). Adenoviral constructs (E1,E3-deleted) encoding either VEGF-A 165 (Ad.VEGF-A), VEGF-D (Ad.VEGF-D) or LacZ (Ad.LacZ) were produced by Ark Therapeutics, Finland, as described. 21 We studied Romney breed time-mated ewes that were pregnant with singleton (n ¼ 3) or twin (n ¼ 3) fetuses between 88 and 102 days of gestation (term 145 days of gestation); the gestational age was confirmed using ultrasound examination of fetal size.
Animals were anesthetized using routine methods 22 and maternal serum and plasma was collected. UtA blood flow (UBF) was measured using Doppler sonography (see method in legend of Figure 1 ). The ewe's abdomen was then opened under strict aseptic conditions by a midline laparotomy and the main UtAs were identified as they passed within the mesometrium either side of the uterus. Ad.VEGF-A (or Ad.VEGF-D in one animal) (5 Â 10 11 particles in 10 ml normal saline) was injected into the most proximal part of one UtA, and Ad.lacZ was injected into the other UtA (the same dose) as a control. Each UtA was occluded manually at its most proximal part and the vector was injected distal to the occlusion over 1 min by a 23-gauge needle; occlusion was maintained for a further 4 min to maximize tissue transfection. The operators were unaware as to which side had received Ad.VEGF vector. The incision was closed and the ewe received standard analgesia and antibiotic prophylaxis. 22 Fetal well-being was monitored post-operation using Doppler ultrasonography of the umbilical artery.
Between 4 and 7 days after adenovirus injection, the ewe was reanesthetized, and UBF Doppler measurements were repeated. We observed that blood volume flow increased by over threefold in Ad.VEGF-A-injected vessels and this increase was significant (Figure 1 ; P ¼ 0.005, two-way analysis of variance (ANOVA) with a General Linear Models (GLIM) function and Tukey pairwise comparisons, Minitab 14; Minitab Inc., State College, PA, USA). Mean (±s.d.) UBF increased from 233 ± 156 ml min À1 to 753 ± 415 ml min
À1
. postinjection UBF was also higher than preinjection levels in the Ad.lacZ-injected vessels but the increase was not significant (mean UBF pre-320+160 ml min À1 and postinjection 430+110 ml min
). There were no significant changes in the umbilical artery diameter, pulsatility index, resistance index or fetal heart rate 4-7 days after injection of adenovirus vectors. Injection of Ad.VEGF-D did not significantly increase UBF (n ¼ 1). While under anesthesia, the abdomen was reopened and the UtAs and their next three divisions down to the level of the uterine wall (vessel diameter 1 mm) were dissected free from uterine tissue and loosely tied. Ewes were then euthanized using an overdose of intravenous pentobarbitone (Euthatal; Rhô ne Merieux, Essex, UK). The UtAs and their branches were ligated and placed into KrebsHenseleit buffer solution (pH 7.4) to be cleaned of fat and adhering tissue; they were divided into five sections for analysis. The maternal and fetal tissues, serum and plasma were sampled.
We found detectable VEGF protein expression in the UtAs of three animals, the uterus of two and the placentome of one animal using VEGF enzyme-linked immunosorbent assay (ELISA) ( Table 1) . Immunohistochemistry confirmed the presence of transgenic VEGF in the UtAs of three animals, all of which had VEGF detectable by ELISA (Figure 2 ). Transgenic lacZ protein expression was detected in the UtAs of three animals using X-gal histochemistry as previously described. 27 (data not shown). LacZ expression was quantified by bgalactosidase ELISA (Table 1) .
UtA samples taken from the first two animals studied were too small for ELISA analysis and insufficient protein was available for analysis. Following these experiments, larger samples of vessels were taken for subsequent ELISA analysis. Maternal and fetal serum and plasma was analysed for the presence of VEGF by ELISA using the same methods as described in Figure 1 Figure 1 Changes in uterine blood flow (UBF) 4-7 days after injection of Ad.lacZ or Ad.VEGF-A. UBF was measured using ultrasonography (Acuson 128 XP10 ultrasound scanner; Siemens, Bracknell, UK, and a C3 3.5 MHz curvilinear transducer) in ventilated ewes maintained at steady state (maternal oxygen and carbon dioxide levels, pulse and respiratory rate and temperature) for 30 min. The time-averaged maximum blood flow (TAMX-V) was measured in the uterine arteries (UtAs) according to standard methodology 2, 12 and corrected for the velocity profile using a spatial velocity distribution coefficient derived in the sheep UtA. 24 The average value of three consecutive cardiac cycles was used for statistical analysis. The vessel diameter, D was measured during systole using color Doppler angiography three times and the average value was used to calculate the vessel area (A) assuming the vessel to have a circular lumen (
. UBF was calculated as the product of the corrected TAMX-V and vessel area as described. 23 All ultrasound measurements were performed by the same investigator (AD). Ewes were reanesthetized 4-7 days after vector injection and measurement of UBF was repeated using Doppler ultrasonography. In Figure 1 , the lines represent the change in UBF 4-7 days after injection of Ad.VEGF-A (solid) or Ad.lacZ (dotted) vectors in individual sheep; group means (with standard deviations) are shown pre-and postinjection of Ad.VEGF-A (black triangle) and Ad.lacZ (black diamond). We observed that blood volume flow increased by over threefold in Ad.VEGF-A-injected vessels and this increase was significant (P ¼ 0.005). No significant increase was seen on the Ad.lacZ-injected side.
Transgenic VEGF increases uterine artery blood flow AL David et al legend. No VEGF was detectable before or 4-7 days after injection.
To determine the extent of spread and expression of the vector in maternal and fetal tissues, we performed reverse transcription (RT)-PCR for detection of Ad.VEGF-A in the following tissues-uterine wall and placenta, maternal and fetal ovary, heart, lung, liver, kidney, adrenal, spleen, brain and thymus. Total RNA was isolated from 30-40 mg of snap-frozen tissues using the RNeasy Mini Kit (Qiagen Ltd, Crawley, West Sussex, UK), as per manufacturer's protocol, with an additional proteinase-K digestion step (following homogenization) at 55 1C for 10 min. Total RNA (1 mg) was reverse transcribed to cDNA using the QuantiTect Reverse Transcription Kit. (Qiagen). The RT step was carried out at 42 1C for 30 min. PCR was performed on the cDNA using the Taq PCR Master Mix Kit (Qiagen). For Ad.VEGF-A, the primers used were designed to span the vector transgene boundary as described {Viita H, 2008 2177 /id}. After denaturation at 94 1C for 4 min, 35 cycles of PCR were performed with denaturation at 94 1C for 45 s, annealing at 64 1C for 45 s, extension at 72 1C for 45 s and a final extension at 72 1C for 10 min. PCR product was not detected in all the samples analysed, indicating there was no undesirable vector spread (data not shown). Primers designed to amplify the endogenous sheep sequences associated with the TATA Box Protein (GenBank reference L47974) were used as a positive control on sheep cDNA and gave no amplification signals from adenovirus DNA alone. PCR conditions used were an initial denaturation at 94 1C for 4 min, 30 cycles of PCR with denaturation at 94 1C for 30 s, annealing at 65 1C for 30 s, extension at 72 1C for 1 min and a final extension at 72 1C for 10 min. All sheep tissue samples gave a product of the appropriate size (127 bp) (data not shown).
Organ bath experiments on UtA sections 4-7 days after injection showed that, compared with Ad.lacZ vessels, there was a significantly reduced mean contractile response to phenylephrine (Emax 148 ± 10.9 vs 228.2±27.5, respectively; n ¼ 5 for both groups; Po0.05, Student's t-test, Figure 3a ) and an increased mean relaxation response to BK (Po0.05) in Ad.VEGF-Atransduced vessels (pD2(Àlog EC 50 ) values were 9.11±0.01 vs 8.65±0.11, respectively; n ¼ 4 for both groups; Po0.05, unpaired t-test and two-way ANOVA; Figure 3b ). This effect could be mediated in part through the ability of VEGF to stimulate endothelial production of NO and prostacyclin by its major signaling receptor KDR (VEGFR2). [17] [18] [19] [20] Treatment with L-NMMA, an inhibitor of NO synthase reduced the relaxant effect of BK in intact UtAs (Po0.05, n ¼ 3) injected with Ad.VEGF-A and Ad.lacZ, although this component only partly contributed to the BK relaxant effect (Figure 4) . Treatment with the cyclooxygenase inhibitor indomethacin did not change the endothelium-dependent relaxation, indicating that PGI 2 does not modulate the relaxation response under these conditions. The remaining endothelium-dependent relaxation (Emax), that was resistant to indomethacin and NO synthase inhibition, was significantly reduced by pretreatment with apamin in Ad.VEGF-A-treated arteries (Figure 4a ; pD2 7.05±0.13, Po0.05, Emax 18.6 ± 1.2, Po0.05, n ¼ 1), and almost abolished with apamin in Ad.lacZ (Figure 4b ; pD2 8.08±0.34, Po0.05, Emax 8.1 ± 3.7, Po0.05, n ¼ 1). Incubation with apamin alone did not significantly change BK-induced relaxation (data not shown).
These data show that intra-arterial injection of an adenoviral vector expressing VEGF-A resulted in VEGF expression in perivascular adventitia and increased UBF 25 The VEGF ELISA kit recognizes both VEGF121 and VEGF165 (soluble forms). Samples were solubilized by homogenization in lysis buffer containing 20 mM hydroxyethyl piperazine ethane sulfonic acid, 0.5 mM ethylene glycol tetraacetic acid, 1 mM dithiothreitiol and 0.32 M sucrose (pH 7.4) for VEGF measurement. Protein content was determined using the method of Bradford (Bio-Rad,UK). VEGF protein concentration in each sample was normalized for total protein concentration in the tissue homogenate. b-galactosidase levels in the UtAs, their branches and the placentomes, were determined by ELISA using a commercially available assay kit (Boehringer Mannheim, Mannheim, Germany). Levels of b-galactosidase were standardized to the protein content of each sample, determined by the bicinchoninic acid protein assay system (Pierce, IL, USA). In all cases the uterine vessels that were injected with Ad.lacZ contained no detectable VEGF protein, and UtAs injected with Ad.VEGF-A or VEGF-D had no detectable b-galactosidase protein.
Survival following the experimental procedure was 100% and there was no significant morbidity in the fetus or ewe noted at postmortem or histological examination of the tissues. The maternal pulse rate, respiratory rate and blood pressure measured at vector injection and terminal anesthesia 4-7 days later, were not significantly different. . Histological sections of maternal tissues were studied (placenta, uterine wall, heart, lung, liver, kidney, adrenal and spleen); no vascular proliferation, inflammatory infiltration, vasodilatation or edema was observed.
(c-h) Vascular endothelial growth factor (VEGF) was detected immunohistochemically using a mouse monoclonal antibody (sc-7269, 1:200; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) followed by a standard avidin-biotin peroxidase method. 26 Negative controls for immunostainings were performed by omitting the primary antibody and using control tissues from a noninjected sheep (f, Â 10). Positive staining is seen in vessels within the perivascular adventitia of the main uterine artery (c, Â 4 and d, Â 20) and its second branch (e, Â 10, g and h, Â 20). In all cases UtAs that were injected with Ad.lacZ had no detectable VEGF protein by enzyme-linked immunosorbent assay (ELISA) or immunohistochemistry analysis and UtAs that were injected with Ad.VEGF-A or VEGF-D had no detectable X-gal staining. significant challenges that need to be addressed before this gene therapy approach to increasing UBF becomes clinically relevant.
The study was designed with clinical relevance in mind. We performed the studies in sheep because many aspects of sheep fetal and vascular physiology are similar to the human and because the ovine fetus is similar in size to the human, allowing use of techniques such as ultrasound-guided fetal injection that are clinically relevant. We measured UBF using ultrasonography, a noninvasive technique used to quantify UBF in normal human pregnancy 23, 29 as well as those complicated by FGR. 24 Quantification of UBF using Doppler has recently been validated in the pregnant sheep in late gestation, and correlated well with direct measurement using implanted flow probes. 24 The measurements of UBF we obtained at 88-102 days of gestation in pregnant sheep were similar to those observed in pregnant humans (300-1000 ml min
) in mid to late pregnancy. 23 Although Doppler measurements of volume blood flow are prone to inter-and intraobserver error, the increase in UBF that we observed after delivery of Ad.VEGF-A was reproducible, indicating that VEGF-A overexpression produced a biologically meaningful enhancement of blood flow 4-7 days postinjection. Previous work from our group has shown that adenoviral vectors (similar to those used in this study) result in highly efficient tissue transfection and expression of transgenic proteins, 27 but that the length of transgene expression is short (up to 3-4 weeks); this would be an advantage in the clinical scenario Figure 3 Contractile and relaxation responses of uterine arteries (UtAs). The main UtAs and their three branches bilaterally were cut into individual ring segments (2-3 mm in length) that were maintained in organ baths according to standard protocols. 28 Concentration response curves to phenylephrine (PE) and bradykinin (BK) were constructed for each vessel in duplicate. Contractile effects were expressed as a percentage of the response to KCl (70 mM) and relaxation was expressed as a percentage of inhibition of PE-induced contraction. pD2 (Àlog EC 50 was the concentration of agonist producing half-maximum effect (EC 50 values). The mean contractile response of the four vessels was calculated. Statistical significance was accepted at Po0.05; n values are presented as the number of ewes. PE produced concentration-dependent contractions, which were of less magnitude in arteries transduced with Ad.VEGF-A compared with Ad.lacZ-transduced vessels (Po0.05, (a)). BK (10 pmol l À1 to 1 mmol l
) caused endothelium-dependent relaxation, which was significantly increased in arteries transduced with Ad.VEGF-A compared with those transduced with Ad.lacZ (Po0.05, (b)). proposed where the aim is short-term expression during a critical stage of pregnancy. It is therefore likely that the increase in UBF we observe at 4-7 days will be sustained for up to 6 weeks; however, further experiments using chronically implanted flow probes that provide well validated, objective measurements of blood flow over long periods of time are indicated. 30 UBF is reduced in pregnancies complicated by FGR when compared to normal pregnancy. One longitudinal case control study in FGR pregnancies showed that UBF was reduced by 12.5% at 20 weeks, and by 36.7% from 24 weeks of gestation until delivery. 31 Thus any therapy for FGR based on increasing UBF to normal levels would need to achieve a 58% increase in UBF, a smaller increase in blood flow than we observed in this study.
This study showed that adenovirus-mediated local overexpression of VEGF results in increased relaxation to BK and reduced contractile response to PE. Apaminsensitive small conductance Ca 2+ -dependent K + channels are implicated in regulation of vascular tone in large arteries mediated by endothelium-derived hyperpolarizing factor (EDHF), and this mechanism may account for the NO/PGI 2 -independent relaxation we observed. However, after blocking the NO, PGI 2 and EDHF pathways, 20% of relaxation to BK remained in the Ad.VEGF-A-treated side compared with 7% remaining in the Ad.lacZ vessels. This may reflect either another as yet unidentified VEGF-mediated relaxation mechanism, or, alternatively, augmentation of NO/EDHF-dependent signaling resulting from VEGF overexpression.
Administration of VEGF-A protein regulates vascular tone through a vasodilatory effect in the adult human vasculature. 32 A physiologically important role of VEGF in maintaining vascular tone and function in the adult human vasculature is supported by the finding that cancer patients treated with the VEGF-A inhibitor, Avastin, have an increased incidence of hypertension, and thromboembolic events such as stroke and myocardial infarction. 32 Augmentation of the vasodilatory effect of VEGF in the uterine vasculature as demonstrated here, raises the possibility of using VEGF-A gene therapy to counteract the abnormal blood flow underlying PET and FGR.
The aim of this study was to achieve overexpression of VEGF localized to the uteroplacental vasculature and thus to avoid systemic complications of high circulating VEGF levels, such as hypotension. No deleterious effects were observed, in that the ewes resumed normal feeding postinjection and there was no fetal mortality or change in umbilical artery Doppler parameters. In addition, the measured increase in UBF suggests that at least at 4-7 days postinjection the animals were not hypotensive. However, these preliminary experiments do not fully assess the possibility of vector or transgene leak to other tissues or indeed transplacentally to the fetus. It is however reassuring that angiographic injection of adenovirus vectors containing the LacZ marker gene into rabbit UtAs was shown to be safe in one study, and produced high levels of transfection in the placental trophoblast; importantly, there was only low level leakage of vector into the fetus. 33 Severe early onset FGR affects 1:500 pregnancies, and is associated with high perinatal mortality and long-term complications in survivors. An affected fetus may never achieve a viable delivery weight (500 g) and the parents face a stark choice between termination of pregnancy, or allowing the fetus to die in utero, as there are no therapies available. A number of national registries have shown that small increases in fetal growth and gestation at birth are associated with major improvements in survival and morbidity. 34, 35 For example, 6-year survival without severe or moderate disability was 24% in babies born at 25 weeks compared with 9% in babies born at 24 weeks of gestation. 36 Babies delivered at 26 weeks of gestation have an increased survival to 1 year according to birth weight, from 51% at a birth weight of 501-600 g to 78% at a birth weight of 601-700 g. 37 It remains to be determined whether a sustained increase in UBF of the magnitude described in this study will be sufficient to promote fetal growth in such adverse circumstances. However, we believe that the data presented here provide the first step in designing a clinical intervention for severe FGR, probably using minimally invasive X-ray-guided catheterization by the femoral artery to access the uteroplacental circulation. 38 The optimum method for delivering therapy, either intraor extraluminal, and the need for vessel occlusion are important factors to investigate. We plan further experiments to determine the safety and feasibility of this gene therapy approach to improving placental perfusion.
